Nicola  Heffron net worth and biography

Nicola Heffron Biography and Net Worth

COO of 2seventy bio
Nicola Heffron is chief operating officer at 2seventy bio. Previously, Nicola was at bluebird bio for almost two years, where she held multiple leadership positions, most recently as chief operating officer of the oncology business unit. She has accumulated over 25 years of experience across R&D, global commercial, and local operational P&L and marketing strategy roles. She led the commercial launch for a global franchise across 16 rare and specialty brands. Most recently Nicola led the Global Myeloid Commercial team at Celgene. Before this, she ran the Global Internal Medicine Franchise for Shire and held a number of leadership roles in R&D and Commercial at global, regional, and affiliate levels at GSK and Eli Lilly. A qualified pharmacist, Nicola holds an M.B.A. from the University of Warwick in the UK.

What is Nicola Heffron's net worth?

The estimated net worth of Nicola Heffron is at least $405,778.10 as of February 7th, 2023. Ms. Heffron owns 89,182 shares of 2seventy bio stock worth more than $405,778 as of April 19th. This net worth approximation does not reflect any other investments that Ms. Heffron may own. Learn More about Nicola Heffron's net worth.

How do I contact Nicola Heffron?

The corporate mailing address for Ms. Heffron and other 2seventy bio executives is , , . 2seventy bio can also be reached via phone at 339-499-9300 and via email at [email protected]. Learn More on Nicola Heffron's contact information.

Has Nicola Heffron been buying or selling shares of 2seventy bio?

Nicola Heffron has not been actively trading shares of 2seventy bio during the last quarter. Most recently, Nicola Heffron sold 60 shares of the business's stock in a transaction on Tuesday, February 7th. The shares were sold at an average price of $14.70, for a transaction totalling $882.00. Following the completion of the sale, the chief operating officer now directly owns 89,182 shares of the company's stock, valued at $1,310,975.40. Learn More on Nicola Heffron's trading history.

Who are 2seventy bio's active insiders?

2seventy bio's insider roster includes William Baird, III (CFO), Philip Gregory (Insider), Nicola Heffron (COO), and Nick Leschly (CEO). Learn More on 2seventy bio's active insiders.

Are insiders buying or selling shares of 2seventy bio?

During the last twelve months, 2seventy bio insiders bought shares 3 times. They purchased a total of 716,414 shares worth more than $3,658,127.44. During the last twelve months, insiders at the sold shares 12 times. They sold a total of 177,739 shares worth more than $768,902.01. The most recent insider tranaction occured on March, 25th when Director Casdin Capital, Llc bought 330,000 shares worth more than $1,673,100.00. Insiders at 2seventy bio own 2.6% of the company. Learn More about insider trades at 2seventy bio.

Information on this page was last updated on 3/25/2024.

Nicola Heffron Insider Trading History at 2seventy bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2023Sell60$14.70$882.0089,182View SEC Filing Icon  
1/11/2023Sell128$10.63$1,360.6489,242View SEC Filing Icon  
1/9/2023Sell584$10.33$6,032.7289,370View SEC Filing Icon  
12/5/2022Sell272$15.43$4,196.9689,954View SEC Filing Icon  
11/21/2022Sell7,697$13.97$107,527.0990,226View SEC Filing Icon  
2/7/2022Sell1,636$16.01$26,192.36View SEC Filing Icon  
2/4/2022Sell467$15.41$7,196.47View SEC Filing Icon  
12/7/2021Sell257$31.06$7,982.42View SEC Filing Icon  
See Full Table

Nicola Heffron Buying and Selling Activity at 2seventy bio

This chart shows Nicola Heffron's buying and selling at 2seventy bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

2seventy bio Company Overview

2seventy bio logo
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.52
Low: $4.46
High: $4.76

50 Day Range

MA: $5.18
Low: $3.96
High: $6.00

2 Week Range

Now: $4.52
Low: $1.53
High: $12.69

Volume

608,615 shs

Average Volume

1,402,908 shs

Market Capitalization

$231.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84